Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
University of California, Irvine
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07447050CT.gov Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | — | Recruiting | — | — | — |
NCT06580002CT.gov Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Urinary System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Riluzole (this asset) | University of California, Irvine | P2 | CCC · 53 |
| Tadalafil | Regina Elena Cancer Institute | P3 | B |
| Nivolumab | Spanish Oncology Genito-Urinary Group | P2 | B |
| Ipilimumab | Dana-Farber Cancer Institute | P2 | B |
| Atezolizumab | British Columbia Cancer Agency | P2 | B |
| Amcasertib | Sumitomo Pharma America, Inc. | P2 | CCC |
| Adriamycin | University of Illinois at Chicago | P1 | CCC |
| Alisertib | University of Illinois at Chicago | P1 | CC |
| Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | P1 | CC |
+21 more in the Malignant Urinary System Neoplasm cohort
Other indications for Riluzole
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Amyotrophic Lateral Sclerosis | — | P4 | BB · 69 |
| Major Depressive Disorder | — | P4 | BB · 68 |
| Cerebellar Ataxia | — | P2/3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Riluzole in Malignant Urinary System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/riluzole-malignant-urinary-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →